80 related articles for article (PubMed ID: 12271926)
1. A patient-directed fee-for-service system can work for ESRD.
Amerling R
Nephrol News Issues; 2002 Sep; 16(10):25-6. PubMed ID: 12271926
[No Abstract] [Full Text] [Related]
2. An alternative to global capitation for ESRD: global fee-for-service.
Amerling R
Nephrol News Issues; 2000 Jul; 14(8):15-6. PubMed ID: 12101516
[No Abstract] [Full Text] [Related]
3. Telemedicine project looks to improve ESRD care, lower costs. TRC/Georgetown University Medical Center begin two-year experiment.
Neumann ME
Nephrol News Issues; 1997 Oct; 11(10):67-9. PubMed ID: 9391397
[No Abstract] [Full Text] [Related]
4. The move away from fee-for-service care.
Dixon-Warren B
CMAJ; 2000 Feb; 162(3):316-7. PubMed ID: 10693585
[No Abstract] [Full Text] [Related]
5. Impact of national health care systems on patient evaluations of general practice in Europe.
Wensing M; Baker R; Szecsenyi J; Grol R;
Health Policy; 2004 Jun; 68(3):353-7. PubMed ID: 15113646
[TBL] [Abstract][Full Text] [Related]
6. Economic efficiency of gate-keeping compared with fee for service plans: a Swiss example.
Schwenkglenks M; Preiswerk G; Lehner R; Weber F; Szucs TD
J Epidemiol Community Health; 2006 Jan; 60(1):24-30. PubMed ID: 16361451
[TBL] [Abstract][Full Text] [Related]
7. HMNo: the name of this practice says it all.
Duke S
Med Econ; 2000 Mar; 77(5):78, 81-2, 84 passim. PubMed ID: 10848414
[No Abstract] [Full Text] [Related]
8. TM failed to differentiate between concierge and direct fee-for-service practices.
Berry RS
Tenn Med; 2007 Jan; 100(1):9-10. PubMed ID: 17285953
[No Abstract] [Full Text] [Related]
9. Patients' health in contract and fee-for-service care. I. A descriptive comparison.
Johansson V; Axtelius B; Söderfeldt B; Sampogna F; Paulander J; Sondell K
Swed Dent J; 2007; 31(1):27-34. PubMed ID: 17508707
[TBL] [Abstract][Full Text] [Related]
10. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
[TBL] [Abstract][Full Text] [Related]
11. Incidence, prevalence, treatment and cost of end-stage renal disease in Indonesia.
Prodjosudjadi W
Ethn Dis; 2006; 16(2 Suppl 2):S2-14-6. PubMed ID: 16774003
[TBL] [Abstract][Full Text] [Related]
12. ESRD as a window into America's cost crisis in health care.
Knauf F; Aronson PS
J Am Soc Nephrol; 2009 Oct; 20(10):2093-7. PubMed ID: 19729435
[No Abstract] [Full Text] [Related]
13. Costs and consequences of ESRD in NC.
Norman M; Young H; Bell RA
N C Med J; 1997; 58(3):165. PubMed ID: 9164124
[No Abstract] [Full Text] [Related]
14. The patient-centered medical home and nephrology.
DuBose TD; Behrens MT; Berns A; Davis C; Goldfarb S; Hostetter T; Klotman P; Linas S; Owens S; Szczech L; Himmelfarb J
J Am Soc Nephrol; 2009 Apr; 20(4):681-2. PubMed ID: 19297553
[No Abstract] [Full Text] [Related]
15. The transition of pediatric to adult-centered health care.
Warady BA; Ferris M
Nephrol News Issues; 2009 Sep; 23(10):49-51. PubMed ID: 19807007
[No Abstract] [Full Text] [Related]
16. The direction of end-stage renal disease reimbursement in the United States.
Lockridge RS
Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
[TBL] [Abstract][Full Text] [Related]
17. Applause, catcalls greet retainer medicine.
Baker S
Manag Care; 2002 Nov; 11(11):40-2. PubMed ID: 12491857
[No Abstract] [Full Text] [Related]
18. Current status of end-stage renal disease care in South Asia.
Jha V
Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
[TBL] [Abstract][Full Text] [Related]
19. Drugs take the spotlight in steering clinical, economic direction for ESRD.
Neumann ME
Nephrol News Issues; 2004 Jun; 18(7):50-1. PubMed ID: 15232997
[No Abstract] [Full Text] [Related]
20. Futuristic plans for ESRD--a new bundled payment system.
Michael M
Nephrol News Issues; 2005 Sep; 19(10):52, 54. PubMed ID: 16187649
[No Abstract] [Full Text] [Related]
[Next] [New Search]
